期刊文献+

胆汁淤积的发病机制和诊治现状 被引量:1

Current Status of Cholestasis:Pathogenesis,Diagnosis and Treatment
下载PDF
导出
摘要 临床常见的胆汁淤积可由多种疾病引起,胆汁生成的任何因素异常、胆汁对肝细胞的损伤和破坏致肝细胞坏死等一系列病理变化可引起肝内、肝外胆汁淤积,其发病机制涉及胆盐转运蛋白、ABC转运蛋白和遗传等因素,其中核受体机制在此过程发挥关键作用。随着生化和影像技术的进步,其诊断水平有所提高。但在治疗方面,除疗效确切的熊去氧胆酸外,目前虽已报道了很多天然和合成的核受体激动剂和拮抗剂可能亦有治疗作用,但有待更大规模、随机、对照临床研究验证。 Cholestasis, the commonly seen syndrome in clinical practice, can be caused by many diseases. Intra- and extrabepatic cholestasis can be caused by various pathological changes including liver cell necrosis, impaired production and excretion of bile which in turn resulting in hepatocyte damage. The mechanistic insights involve bile salt transporters, ATP-binding cassette transport proteins, heredity and so on, in which the nuclear hormone receptor plays a pivotal role. With the advancement in biochemical and imaging techniques, the diagnostic capability increased significantly. Although advances have been achieved in the management of cholestasis, ursodexycholic acid (UDCA) is still the only effective treatment available. Although lots of natural and synthetic agonists and antagonists of nuclear hormone receptor have been reported to be potentially effective, yet more extensive, randomized and controlled clinical studies remain to be needed.
出处 《胃肠病学》 2012年第7期385-388,共4页 Chinese Journal of Gastroenterology
关键词 胆汁淤积 发病机制 诊断 治疗 Cholestasis Pathogenesis Diagnosis Therapy
  • 相关文献

参考文献21

  • 1曲颖,徐铭益,陆伦根.胆汁淤积和自身免疫性肝病研究进展暨“第一届胆汁淤积和自身免疫性肝病专题学术研讨会”纪要[J].临床肝胆病杂志,2011,27(2):222-225. 被引量:5
  • 2Trauner M, Boyer JL. Bile salt transporters : molecular characterization, function, and regulation [J]. Physiol Rev, 2003, 83 (2) : 633-671.
  • 3Lee JM, Trauner M, Soroka C J, et al. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat [J]. Gastroenterology, 2000, 118 (1):163-172.
  • 4Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases [J]. Hepatology, 2001, 33 (3): 633-646.
  • 5Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis[J]. J Hepatol, 2003, 38 (6) : 717-727.
  • 6Oswald M, Kullak-Ublick GA, Paumgartner G, et al. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis [J]. Liver, 2001, 21 (4) : 247-253.
  • 7Marinelli RA, Lehmann GL, Sofia LR, et al. Hepatocyte aquaporins in bile formation and cholestasis [J]. Front Biosci, 2011, 17 : 2642-2652.
  • 8Sinal C J, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis[J]. Cell, 2000, 102 (6): 731-744.
  • 9Kok T, Hulzebos CV, Wolters H, et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein[J]. J Biol Chem, 2003, 278 (43): 41930-41937.
  • 10Zollner G, Fickert P, Fuchsbichler A, et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine [J]. J Hepatol, 2003, 39 (4): 480-488.

共引文献4

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部